NDRA (ENDRA Life Sciences) EBIT: $-6.47 Mil (TTM As of Mar. 2026)


NDRA ENDRA Life Sciences Inc NDRA
25 GF Score
Price $4.30
! 2 Warning Signs
View Full Analysis

What is ENDRA Life Sciences EBIT?

ENDRA Life Sciences NDRA -31.42% 25 EBIT is $-6.47 Mil as of Mar. 2026. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

ENDRA Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ENDRA Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 was -286.95%. ENDRA Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,794.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -116.23%.

ENDRA Life Sciences  (NAS:NDRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ENDRA Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.696 * ( 1 - 0% )/( (3.021 + 3.04)/ 2 )
=-8.696/3.0305
=-286.95 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.854 - 0.616 - ( 0.762 - max(0, 0.751 - 0.968+0.762))
=3.021

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.438 - 0.696 - ( 0.356 - max(0, 0.835 - 0.537+0.356))
=3.04

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ENDRA Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.696/( ( (0.504 + max(-0.416, 0)) + (0.465 + max(-0.52, 0)) )/ 2 )
=-8.696/( ( 0.504 + 0.465 )/ 2 )
=-8.696/0.4845
=-1,794.84 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.206) - (0.616 + 0 + 0.006)
=-0.416

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.181) - (0.696 + 0 + 0.005)
=-0.52

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ENDRA Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6.468/5.565
=-116.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENDRA Life Sciences EBIT Related Terms

ENDRA Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for ENDRA Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENDRA Life Sciences EBIT Chart

ENDRA Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.50 -13.16 -10.52 -10.82 -5.76

ENDRA Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.47 -1.30 -1.37 -1.62 -2.17

NDRA vs NOTV, XWEL, ADVB: EBIT Comparison

For the Diagnostics & Research subindustry, ENDRA Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENDRA Life Sciences EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's EV-to-EBIT falls into.


NDRA
25GF Score
ENDRA Life Sciences Inc NDRA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENDRA Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.47 Mil mean?
ENDRA Life Sciences (NDRA) has a EBIT of $-6.47 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ENDRA Life Sciences.
Is ENDRA Life Sciences' EBIT too high?
ENDRA Life Sciences' current EBIT is $-6.47 Mil. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' EBIT compare to NOTV and XWEL?
ENDRA Life Sciences' EBIT of $-6.47 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ENDRA Life Sciences. ENDRA Life Sciences's current EBIT is $-6.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current EBIT of $-6.47 Mil. The current EBIT is $-6.47 Mil. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current EBIT is $-6.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ENDRA Life Sciences Business Description

Address 3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score

Get the complete analysis for NDRA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price